Valion Bio investor 3i reports 9.9% stake
3i-affiliated holders report 9.9% beneficial ownership of Valion Bio after a 1-for-25 reverse split, while Tumim Stone Capital reports no remaining stake.
Rhea-AI Filing Summary
Valion Bio, Inc. (VBIO) received Amendment No. 7 to a Schedule 13D from 3i, LP, 3i Management LLC and Maier J. Tarlow, updating their ownership after recent transactions and a reverse stock split. The reporting group now has beneficial ownership of 132,671 shares of Common Stock, representing 9.9% of the outstanding common stock, based on 1,285,626 shares outstanding as of August 24, 2026.
The 132,671 shares include 90,252 shares of common stock held by 3i, LP and 42,419 shares issuable upon a combination of warrant exercises and conversions of a senior secured convertible note and Series B and Series C Convertible Preferred Stock, all subject to a 9.99% beneficial ownership limitation. Tumim Stone Capital, LLC now reports 0 shares beneficially owned. All share figures reflect Valion Bio’s 1-for-25 reverse stock split effective August 31, 2026.
Positive
- None.
Negative
- None.
Key Figures
Key Terms
beneficial ownership financial
Series B Convertible Preferred Stock financial
Series C Convertible Preferred Stock financial
beneficial ownership limitation financial
senior secured convertible note financial
reverse stock split financial
FAQ
What stake in Valion Bio (VBIO) do the 3i reporting persons disclose in Amendment No. 7?
What does Tumim Stone Capital, LLC report as its ownership in Valion Bio (VBIO)?
What reverse stock split did Valion Bio (VBIO) implement and when did it become effective?
What is the size of the senior secured convertible note referenced in the VBIO Schedule 13D/A?
AI-generated analysis. How Rhea-AI works. Not financial advice.